You are here
ASTRAZENECA suxamethonium chloride 100mg/2mL injection BP ampoule - medicine shortage
AstraZeneca have advised that the shortage of AstraZeneca Suxamethonium chloride 100mg/2mL injection BP ampoule, ARTG 11988, is now resolved and supply is available through normal supply channels.
18 March 2015
Health professionals are advised that AstraZeneca has submitted a Medicine shortage notification for ASTRAZENECA suxamethonium chloride 100mg/2mL injection BP ampoule (AUST R 11988). The shortage is due to supply disruption and there are no safety concerns with existing supplies.
The shortage is expected to be resolved by May 2015.
The TGA is working with AstraZeneca and other sponsors to enable supply of an alternative suxamethonium product from an approved European source in lieu of the registered product through section 19A exemption ASTRAZENECA suxamethonium chloride 100mg/2mL injection BP ampoule is indicated for the production of skeletal muscle relaxation in anaesthesia. The product is suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.
Information for anaesthetists
AstraZeneca is in the process of contacting Australian anaesthetists, directors of anaesthesia departments, accident and emergency departments, hospital pharmacies and Public and Private Hospital Contract/Tender boards to inform them of the medicine shortage.
Consumers and health professionals are encouraged to report problems with medicines, vaccines or medical devices. Your report will contribute to the TGA's monitoring of these products.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse events associated with a medicine, vaccine or medical device.